Clinical Impact of 2-Deoxy-2-[18F]fluoro-D-Glucose (FDG)-Positron Emission Tomography (PET) on Treatment Choice in Recurrent Cancer of the Cervix Uteri.
The superiority of positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) over computed tomography and magnetic resonance imaging in detecting recurrent cervical cancer and determining the extent of the disease has been demonstrated in several clinical trials. However, there is a lack of data concerning the clinical impact of the extra findings. We report here a prospective